Igenica raises $24 million series B to fund antibody discovery for oncology treatment
This article was originally published in Scrip
Executive Summary
Igenica has raised $24 million in a series B round of financing led by existing investors The Column Group, OrbiMed Advisors and 5AM Ventures. The US company is integrating two technology platforms to develop antibody-based anticancer therapeutics.